Iovance Biotherapeutics (NASDAQ: IOVA) saw its shares climb 9.4% in Tuesday trading, closing at $4.44, after the company unveiled a new at-the-market (ATM) equity offering worth up to $89.65 million. The stock hit an intraday high of $4.52 with volume surging to approximately 17.9 million shares, adding roughly $159 million in market capitalization. The move came as investors weighed the potential dilution from the share sale against the prospect of faster commercialization for the company's lead therapy, Amtagvi.
The ATM offering, managed by Jefferies, allows Iovance to sell shares gradually into the open market rather than in a single block. This structure is seen as less disruptive than a traditional shelf offering. The company noted that it has already sold approximately $260.35 million under a prior prospectus and will discontinue that older filing. At the assumed offering price of $3.93 per share, the full $89.65 million would equate to roughly 22.8 million new shares, representing about 5.2% of Iovance's outstanding share count of 438.1 million as of March 31.
Iovance stated that the proceeds from the offering will support the commercial rollout of Amtagvi, a personalized TIL therapy for advanced melanoma, as well as ongoing clinical trials, including the IOV-LUN-202 study in non-small cell lung cancer and the TILVANCE-301 trial in melanoma. The company's interim CEO, Frederick Vogt, emphasized in May that the organization is accelerating Amtagvi adoption and commercial expansion amid record demand, while also focusing on manufacturing efficiencies and cost reductions to improve margins.
The equity raise comes at a time when growth stocks broadly faced headwinds. The Nasdaq Composite fell 2.2% and the S&P 500 slipped 1.4% on Tuesday. However, the biotech sector showed relative strength, with the SPDR S&P Biotech ETF (XBI) gaining 0.8% and the iShares Nasdaq Biotechnology ETF (IBB) adding 0.6%. Iovance's performance underscores investor confidence in its commercial trajectory.
Iovance has transitioned from a development-stage company to a commercial entity. In the first quarter, the company reported product revenue of $71.43 million, up from $49.32 million in the same period last year. U.S. Amtagvi sales accounted for approximately $60 million, while Proleukin contributed $11 million. For the full year 2026, Iovance targets product revenue in the range of $350 million to $370 million. The company expects second-quarter product revenue of $86 million to $88 million, with U.S. Amtagvi sales projected at $79 million to $81 million.
Access and turnaround times remain critical for Amtagvi's success. Iovance noted that demand and referrals are increasing at over 90 authorized treatment centers in the U.S. and Canada, with a goal of at least 110 active centers by year-end. The company also reported that the manufacturing turnaround time for Amtagvi is 32 days or less, a key metric for a personalized cell therapy where delays can impact revenue. Additionally, Australia recently granted conditional approval for Amtagvi in advanced melanoma, marking the third marketing authorization for the therapy. Vogt highlighted Australia's importance given its highest melanoma rate globally.
The competitive landscape for solid-tumor cell therapies remains relatively uncrowded but notable. Adaptimmune's Tecelra, an autologous T-cell therapy for synovial sarcoma, received FDA accelerated approval in 2024, but Adaptimmune has since agreed to sell Tecelra and its cell-therapy assets to US WorldMeds. This leaves Iovance as a key player in the space, with investors closely watching its ability to finance the launch and pipeline development.
Iovance's balance sheet was a driving factor behind the ATM. The company ended the first quarter with $319.4 million in cash, equivalents, short-term investments, and restricted cash. Its operating cash burn was $72.1 million in the first quarter, meaning the full $89.65 million draw would cover approximately 1.2 quarters at that spending rate. The company has flagged the risk of immediate and substantial dilution from the ATM, and that a large share sale could pressure the stock price. Key risks include slower-than-expected Amtagvi uptake, payer pushback, manufacturing issues, or weak clinical data.
Tuesday's rally suggests that investors are betting the equity raise will fuel Amtagvi's rollout and clinical progress rather than serve as a bailout. If Iovance meets its second-quarter revenue guidance, the market may view the dilution as manageable, supporting the stock's upward momentum.
